EA1131: Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy versus Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Aims: The purpose of this study is to compare the usual approach, which is no further treatment to receiving additional chemotherapy after surgery. 
Diagnosis: Triple negative breast cancer
Principal Investigator: James Ward, MD
IRB Approval Number: EH15-332
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes 

Merck 3475-355 A Randomized , Double-Blind, Phase III Study of  Pembrolizumab (MK-3475) plus Chemotherapy vs. Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)
Aims: The purpose of this study is to compare the the addition of Pembrolizumab to chemothearpy for women whose cancer has recurred. 
Diagnosis: Triple negative breast cancer
Principal Investigator: James Ward, MD
IRB Approval Number: EH16-271
Sponsor: Merck
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

AFT-05 PALLAS: PALbociclib Collaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2) negative early breast cancer
Aims:
The purpose of this study is to compare the addition of palbociclib with the usual hormone therapy for women with early stage breast cancer.
Diagnosis: 
Breast cancer
Principal Investigator:
James Ward, MD
IRB Approval Number:
EH15-286
Sponsor:

Contact:
Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: 
 Yes 

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Aims: The purpose is to study patients who have cancer cells in the lymph nodes when they are diagnosed with breast cancer and have chemotherapy before surgery that clears the cancer cells from the lymph nodes. The study will find out if after lumpectomy, radiation to the breast and lymph nodes will be better than radiation only to the breast at keeping the cancer from returning and if after mastectomy, radiation to the area where the breast used to be and to the lymph nodes, is better than no radiation to keep the cancer from recurrence.
Diagnosis: Breast cancer
Principal Investigator: James Ward, MD
IRB Approval Number: EH15-334
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes 

CBYL719C2301:SOLAR-1: A Phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment
Aims: To find out if the experimental drug alpelisib is safe and has beneficial effects when given with the commercially available drug fulvestrant to men or postmenopausal women with hormone receptor-positive breast cancer
Diagnosis: Breast cancer
Principal Investigator: James Ward, MD
IRB Approval Number: EH15-312
Sponsor: Novartis Pharmaceuticals
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes 

UC13-1-000: Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Aims: The purpose of this study is to find the safest dose of mifepristone when given with standard chemotherapy using carboplatin and gemcitabine. The study will look at the side effects, how your body processes the drugs, and the effects of the drug combination on your body and your cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-248
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Aims: The purpose of this study is to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug Administration (FDA) of the United States for use after surgery for postmenopausal women with estrogen receptor positive breast cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-308
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

Developing and Maintenance of a Comprehensive Breast Reconstruction Registry at NorthShore University HealthSystem
Aims: To track long-term satisfaction following breast reconstruction.
Diagnosis: Breast cancer. Participants must enroll prior to breast reconstruction surgery.
Principal Investigator: Mark Sisco, MD
IRB Approval Number: EH11-124
Sponsor: NorthShore University HealthSystem
Contact: Interested patients may contact Jen Jaffe  847.570.2803, jjaffe@northshore.org
Open to Enrollment: Yes

The NorthShore Study of Surgical Decision-Making and Quality of Life Outcomes after Breast Cancer Surgery
Aims: To discover the decision-making pathway in newly diagnosed breast cancer patients.
Diagnosis: Breast cancer. Participants must enroll prior to breast surgery.
Principal Investigator:
Mark Sisco, MD
IRB Approval Number:
EH14-218
Sponsor: NorthShore University HealthSystem
Contact: Interested patients may contact Agnes Brugger, RN, CCRP 847.570.1632, kbrugger@northshore.org
Open to Enrollment: Yes

Using Genetic Risk Scores to Assess the Efficacy of Mammography Screening Among Women Diagnosed with Breast Cancer
Aims: The study is looking at whether one's Genetic Risk Score (GRS) along with other risk factors will aid in identification of a subgroup of women at high risk for breast cancer in need of increased surveillance.
Diagnosis: Breast Cancer
Principal Investigator: Catherine Pesce, MD
IRB Approval Number: EH15-308
Sponsor: NorthShore University HealthSystem
Contact: Interested patients may contact Sarah Rabbitt, RN, CCRP at 847.570.1681, srabbitt@northshore.org or Sandra Simovic at 847-570-4227, ssimovic@northshore.org
Open to Enrollment: Yes

A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Aims: The purpose of this study is to test whether patients undergoing breast MRI (magnetic resonance imaging) before breast surgery will have better results after the surgery. Breast tumors are routinely evaluated during mammograms and ultrasound before surgery. This study would like to find out if using MRI in addition to mammography before surgery improves our ability to evaluate tumors and decide what kind of surgery is best for the patient.
Diagnosis: Breast Cancer, Clinical Stage I-II
Principal Investigator: Katherine Yao, MD
IRB Approval Number: EH14-346
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients may contact  Sarah Rabbitt, RN at 847.570.1681 srabbitt@northshore.org
Open to Enrollment: Yes

Germline Genetic Profiles Associated with Contralateral Breast Cancer Patients
Aims: To determine whether or not women diagnosed wtih contralateral breast cancer have higher incidences of know breast cancer-risk associated genetic alterations 
Diagnosis: Breast Cancer
Principal Investigator: Katherine Yao, MD
IRB Approval Number: EH16-063
Sponsor: NorthShore University HealthSystem
Contact: Interested patients may contact Sarah Rabbitt, RN at 847.570.1681, srabbitt@northshore.org or Sandra Simovic at 847.570.1681, ssimovic@northshore.org
Open to Enrollment: Yes

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection. 
Diagnosis: Breast Cancer, Clinical Stage II-IIIA
Principal Investigator: Catherine Pesce, MD
IRB Approval Number: EH15-297
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients may contact  Sarah Rabbitt, RN at 847.570.1681, srabbitt@northshore.org
Open to Enrollment: Yes

NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in patients with Germline BRAC1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Aims: The purpose of this study is to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation for your type of cancer. In this study, you will get either olaparib or placebo.
Diagnosis: BreastGermline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-400
Sponsor: NSABP
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A221405: Pregnancy Outcome and Safetry of Interrupting Therapy for Women wtih Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE)
Aims: The purpose of this study is to determine how long a woman should wait before trying to become pregnant after breast cancer treatment.  The study will collect information about the success of pregnancy, health of newborn, and patient's ability to breastfeed.
Diagnosis: nd High Risk HER2 Negative Primary Breast Cancer
Principal Investigator: James Ward, MD 
IRB Approval Number: EH16-224
Sponsor: Alliance
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes